< Back to previous page

Patent

Biomarkers for disease burden of neuroblastoma

The present invention relates to monitoring disease and therapy response. More in particular, the present invention discloses serum/plasma miRNA markers for assessment of disease burden in human neuroblastoma. Indeed, the present invention discloses that the more the tumor is spread throughout the body, the higher the levels of particular miRNAs in serum/plasma are. Consequently, the latter markers can be used in methods and kits for assessing the neuroblastoma disease burden.
Patent Publication Number: EP3724356
Year filing: 2018
Year approval: 2024
Year publication: 2024
Status: Requested
Technology domains: Biotechnology
Validated for IOF-key: Yes
Attributed to: Associatie Universiteit Gent